QualityStocks would like to highlight GeoVax Labs (OTCBB: GOVX), a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS). The company’s goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward.
In the company’s news yesterday,
GeoVax Labs announced that it has opened a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the
The study will last up to 77 weeks for each participant. To be eligible, volunteers need to be diagnosed within the first year of HIV infection and they must have started antiretroviral drug therapy within six months of diagnosis. Researchers will monitor the participants closely to assess vaccine safety and will watch for the ability of the vaccine to induce therapeutic immune responses.
Mark Newman, PhD, Vice President of Research and Development at GeoVax, commented, “We are very pleased to be expanding this important clinical trial to include the AVRC, a group with which we have worked successfully for several years.”
UAB joins the AIDS Research Consortium of Atlanta (ARCA) as the second site used for this trial. Sonya Heath, MD, the medical director for the study at UAB, said, “New approaches to HIV treatment are critically needed, and an effective therapeutic vaccine would be an important tool in our ongoing efforts to treat people with HIV infection. A vaccine that enhances the body’s ability to control HIV and decreases the dependence on antiretroviral drugs would be a major breakthrough.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
